Health Sciences Authority

The Health Sciences Authority (HSA) is Singapore's multidisciplinary health-sciences and regulatory agency. HSA was established as a statutory board under the Ministry of Health on 1 April 2001, integrating five former national agencies (HSA, milestones). Its mission is to regulate health products wisely, serve the administration of justice, secure the nation's blood supply and safeguard public health (HSA, vision, mission and values).

Three professional groups and core functions

HSA's work is organised around three main professional groups. Health Products Regulation regulates health products against standards of safety, quality and efficacy, covering work such as product registration, licensing and post-market safeguards for relevant product classes. Blood Services secures a safe and adequate blood supply for public and private hospitals, alongside blood-banking and specialised laboratory work supporting transfusion and transplantation medicine. Applied Sciences provides forensic medicine, forensic science and analytical-chemistry testing that supports the administration of justice and public health (HSA, About us, rechecked 12 September 2026). These functions make HSA both a health-products regulator and a national scientific service. A question about a product licence, a blood donation or a forensic laboratory service may therefore involve different HSA teams and rules; “HSA” is not synonymous with a single licensing process.

Health-products regulation

HSA's regulatory scope includes product registration, licensing, notifications, advertisements and safety monitoring across different product classes. The exact route depends on the product: HSA separately describes pathways for therapeutic products, medical devices, cell, tissue and gene therapy products, cosmetics, Chinese proprietary medicines, traditional medicines, health supplements, tobacco products and other regulated products (HSA, home). A product appearing on an HSA pathway does not mean that every product class has identical pre-market requirements, licence conditions or evidence standards.

HSA's regulatory role also supports Singapore's biomedical and pharmaceutical ecosystem. Its decisions and scientific assessments concern regulated products and public-health safeguards; they should not be interpreted as a guarantee that a product is clinically appropriate for every individual or as a substitute for advice from a healthcare professional.

Blood and applied-science services

Through Blood Services, HSA operates the national blood-service function and works to maintain a safe and adequate supply for hospitals (HSA, About us). Through Applied Sciences, it contributes specialised forensic, investigative and analytical capabilities to the administration of justice. The two functions have different users and decision contexts: blood services support transfusion and hospital supply, while applied-science services support justice, public-health and government investigations. Neither should be collapsed into the health-products licensing function.

For retrieval purposes, these services also imply different next steps. A person seeking to donate blood or understand blood-bank services should use HSA's blood-services and donation information; a court, investigator or public agency seeking laboratory or forensic support should use the relevant applied-science channel. Neither service is a general clinical-care provider, and the About Us description does not turn an analytical result into a diagnosis or a forensic examination into a regulatory approval. Keeping these boundaries explicit helps distinguish HSA from hospitals, MOH policy functions and product manufacturers while retaining the agency's shared public-health mission.

Integrated healthcare-regulation transition

HSA's integrated-regulation page, updated 2 October 2026, describes a two-phase move from MOH to HSA. In Phase 1, scheduled for November 2026, MOH's Health Regulation Group (HRG) manpower and functions move to HSA, including administration, licensing, inspections, audits and enforcement under MOH Acts. From November, the page lists stakeholder engagement with HSA for healthcare-service licensing and approvals under the Healthcare Services Act (HCSA); notifications and approvals under the Human Biomedical Research Act (HBRA); facility registration and certification-body registration under the Biological Agents and Toxins Act (BATA); cybersecurity, data-security and National Electronic Health Record matters under the Health Information Act (HIA); the Health Sector Administrator role for charities and Institutions of a Public Character; and health-product registration and dealer licensing under the Health Products Act (HPA) (HSA, integrated healthcare regulation, updated 2 October 2026 and rechecked 3 October 2026).

Phase 2, by end-2027, concerns the manpower and functions of the Secretariat of healthcare Professional Boards (SPB), including policy, guideline and process support for the Professional Boards and Councils. The page distinguishes that secretariat support from professional regulation itself: registration and other regulatory work relating to healthcare professionals continue to reside with SPB until further communicated by end-2027. The professional boards remain the bodies whose statutory mandates govern their respective professions; the announced organisational move does not mean HSA makes all professional registration decisions (HSA, integrated healthcare regulation, updated 2 October 2026 and rechecked 3 October 2026).

HSA says stakeholders and licensees need not reapply for existing licences, approvals or registrations, and that submission channels, processing arrangements and regulatory requirements continue during the transition. Until the relevant change takes effect, these are scheduled transfers, not proof that all HRG functions already moved. The transition changes the agency responsible for specified administrative and enforcement functions, with professional-board secretariat support following later; it does not itself announce new substantive licensing requirements (HSA, integrated healthcare regulation, updated 2 October 2026 and rechecked 3 October 2026).

The transition is intended to bring regulation of healthcare services, products, information, biomedical research, healthcare charities and professional-regulation support into a more integrated hub (HSA, integrated healthcare regulation, updated 2 October 2026 and rechecked 3 October 2026). HSA's current About page describes three distinct core functions—health-products regulation, blood services, and applied sciences supporting justice—which remain useful when distinguishing the authority's longstanding roles from the new cross-government transition (HSA, About us, updated 21 September 2026 and rechecked 3 October 2026). HSA's milestones page also records that in 2025 it implemented a Next-Gen Blood Supply Management System across all public hospitals, illustrating that the authority's operational role includes national systems as well as licensing and enforcement (HSA, milestones, page last updated 13 March 2026 and rechecked 12 September 2026). Existing HSA product-regulation pages and the separate professional-board framework should therefore be read with the applicable phase and effective date in mind.